Product image of Linagliptina Generis (Linagliptin) supplied by GNH India

Linagliptina Generis

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Generis (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Generis, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.
GNH India supplies Linagliptina Generis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is used to improve glycaemic control in patients with type 2 diabetes mellitus, acting on the incretin pathway.

  • Type 2 diabetes mellitus: improves glycaemic control as monotherapy.
  • Type 2 diabetes mellitus (combined with metformin): enhances overall glucose lowering.
  • Type 2 diabetes mellitus (adjunct to diet and exercise): supports maintenance of target HbA1c levels.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, leading to reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper respiratory infection symptoms.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: cough, sore throat.
  • Gastrointestinal discomfort: nausea or abdominal pain.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Severe hypoglycaemia: when combined with insulin or sulfonylureas.

Precautions & Warnings

Before prescribing Linagliptina Generis, clinicians should consider several safety aspects.

  • Renal impairment: assess kidney function; dose adjustment may be needed.
  • Hepatic impairment: monitor liver enzymes and adjust therapy if necessary.
  • Cardiovascular disease: use with caution in patients with unstable heart conditions.
  • Concomitant antidiabetic agents: monitor for increased risk of hypoglycaemia.
  • Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure.
  • Insulin or sulfonylureas: can increase risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

  • Diuretics: monitor electrolytes and renal function.
  • Warfarin: observe INR values for potential anticoagulant effect changes.

Frequently Asked Questions

Linagliptina Generis contains linagliptin, a DPP‑4 inhibitor indicated to improve blood glucose control in adults with type 2 diabetes mellitus, usually as part of a comprehensive treatment plan that includes diet and exercise.

Linagliptin blocks the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving incretins such as GLP‑1 and GIP, it enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions exactly.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Linagliptina Generis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin stimulation without causing weight gain, unlike some sulfonylureas or insulin. Compared with GLP‑1 receptor agonists, it is oral, has a lower risk of gastrointestinal side effects, but may be less potent in reducing HbA1c.

Linagliptina Generis should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious but rare risks include pancreatitis, severe allergic reactions such as anaphylaxis, and liver injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptina Generis is contraindicated in patients with known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnancy unless clearly needed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT